Hengrui Medicine's (01276) application for the market approval of injection regorafenib monoclonal antibody for a new indication has been accepted and included in the priority review process.

Zhtng Cijng APP News, Hengrui Medicine (01276) announced that its subsidiary, Suzhou Shengdiya Biomedical Medicine Co., Ltd., recently received a "Notice of Acceptance" issued by the National Medical Products Administration for the injection of Rui Kang trastuzumab emtansine (SHR-A1811) used in the treatment of locally advanced or metastatic HER2-positive adult breast cancer patients who have previously received one or more anti-HER2 drugs, The new indication for the market approval application has been accepted by the National Medical Products Administration and has been included in the priority review process.